Table: Eisai -Q1 group results (IFRS)
Aug 5 (Reuters)-
Eisai Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2025 Jun 30, 2024 Mar 31, 2026
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 202.65 189.03 790.00
(+7.2 pct) (-4.0 pct) (+0.1 pct)
Operating 20.74 13.41 54.50
(+54.7 pct) (-48.5 pct) (+0.2 pct)
Pretax 22.40 15.97 59.00
(+40.3 pct) (-43.5 pct) (-3.4 pct)
Net 14.47 10.58 41.50
(+36.8 pct) (-48.0 pct) (-10.6 pct)
EPS Basic 51.35 yen 36.95 yen 147.20 yen
Ann Div 160.00 yen 160.00 yen
-Q2 Div 80.00 yen 80.00 yen
-Q4 Div 80.00 yen 80.00 yen
NOTE - Eisai Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4523.T
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China